Upstream Bio shares rise 10.03% in intraday after Verekitug Phase 3 strategy and positive VALIANT trial results announced.

Upstream Bio surged 10.03% in intraday trading, driven by the announcement of a Phase III development strategy for verekitug, including plans to launch trials for severe asthma and CRSwNP in Q1 2027 and reporting positive VALIANT trial results showing a 56% reduction in asthma exacerbations, with cash reserves of $341.5 million expected to sustain operations through 2027.